Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rituxan Launch For Arthritis, Tysabri Return Expected In Mid-’06, Biogen Says

Executive Summary

Biogen Idec could launch Rituxan (rituximab) for rheumatoid arthritis and relaunch Tysabri (natalizumab) for multiple sclerosis by mid-2006, CFO Peter Kellogg said during an Oct. 26 earnings call
Advertisement

Related Content

Rituxan RA Approval Raises The Stakes, But With A Lower Price
Rituxan RA Approval Raises The Stakes, But With A Lower Price
Tysabri Safety Study To Commence Following Lift Of Clinical Hold
Tysabri Safety Study To Commence Following Lift Of Clinical Hold
Biotech M&A Primed For 2006: Vertex Pharmaceuticals Could Lead Off Banner Year Of Biotech Buys
Bristol Gears Up For Orencia Launch With Creation Of Immunoscience Unit
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
Tysabri Resubmission: Early Safety Test For New Commissioner
Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS046499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel